I have been doing some reading, and the bottom line is that prostate cancer is a huge... and interesting market. If these trials are successful this company will fly. There are currently limitations for surveillance and curative options to manage low risk clinically localised prostate cancer. Not much collateral damage around prostate as it is basically useless but erectile dysfunction a real concern ....and prostatectomy not needed or wanted for the low risk. Non invasive PDT could be a solution for this cohort.
IVX Price at posting:
0.7¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)